Point To Point Methodics Stock (OTC: PPMH)

Latest news for Point To Point Methodics (OTC:PPMH) Stock

Point To Point Methodics Inc is focused on innovation and enterprise by acquiring, managing, and operating technology-based companies for growth within the industry. The company's products and services span the following markets: Automotive, Business Intelligence, Digital Sociology, Educational Applications, Game Applications, Homeland Security, Informational Understanding, Mobile Applications, Mobile Mapping, Public Safety, and Social Media. It serves both domestic and international markets.

POINT TO POINT METHODICS by Point to Point Methodics, Inc.

Point To Point Methodics Inc

Goldman Sachs analyst Mike Harris initiates coverage on Cleveland-Cliffs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) with a Buy rating and announces Price Target of $16.

News

Price Target

Initiation

Analyst Ratings

Goldman Sachs Initiates Coverage On Cleveland-Cliffs with Buy Rating, Announces Price Target of $16

The Company intends to contribute the net proceeds to Strawberry Fields Realty, LP, its operating partnership, which will in turn use the proceeds from this offering to finance acquisitions of new investments, pay down existing debt, and for general corporate purposes.

REIT

Offerings

General

Real Estate

STRW

Strawberry Fields REIT Has Commenced An Underwritten Public Offering Of Its Common Stock. The Company Also Intends To Grant The Underwriters A 30-day Option To Purchase Up To An Additional 15% Of The Shares Offered In The Offering

Biotech

Health Care

OCUL

Ocular Therapeutix Announced That More Than 300 Patients Have Been Randomized In SOL-1 Phase 3 Trial For Axpaxli (Axitinib Intravitreal Implant, Or OTX-TKI) For Wet Age-related Macular Degeneration, And The Trial Is Expected To Close Randomization This Week, Topline Data Are Expected In Q4 Of 2025

Goldman Sachs analyst Mike Harris initiates coverage on Commercial Metals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMC#NYSE">CMC</a>) with a Buy rating and announces Price Target of $75.

Goldman Sachs Initiates Coverage On Commercial Metals with Buy Rating, Announces Price Target of $75

<ul>
<li>Based on attendance at its U.S. theatres, AMC enjoyed its busiest pre-Thanksgiving Wednesday, busiest Thanksgiving Day, busiest Black Friday, and busiest 5-day Thanksgiving holiday period in the Company's 104-year history</li>
<li>Friday, November 29 was AMC's highest total revenue (admissions plus food &amp; beverage revenue) Friday of all time, second busiest Friday of all time, and the second-highest total revenue day in AMC history</li>
</ul>

Entertainment

AMC Theatres Said 8.8M Moviegoers Attended A Movie At AMC Theatres In The U.S. And ODEON Cinemas Internationally During The Wednesday Through Sunday Thanksgiving Period

<ul>
<li>Compelling Phase 1/1b update on RMC-6236 monotherapy in second-line metastatic pancreatic ductal adenocarcinoma supports ongoing Phase 3 RASolute 302 clinical trial</li>
<li>Phase 1/1b proof-of-concept for RMC-6236 monotherapy in previously treated non-small cell lung cancer supports Phase 3 RASolve 301 clinical trial expected to be initiated in Q1 2025</li>
<li>Favorable initial safety profile for combination of pembrolizumab with either RMC-6236 or RMC-6291 supports continued evaluation in non-small cell lung cancer</li>
<li>Initial antitumor activity of RMC-6236 and RMC-6291 combination in heavily pretreated colorectal cancer supports RAS(ON) inhibitor doublet treatment strategy</li>
</ul>

RVMD

Revolution Medicines Announced Key Clinical Updates From Its RAS(ON) Inhibitor Portfolio

Evercore ISI Group analyst Mark Mahaney maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Outperform and raises the price target from $775 to $950.

NFLX

Evercore ISI Group Maintains Outperform on Netflix, Raises Price Target to $950

SNGX

Soligenix Announced That Analysis Of The Post-treatment Data From The Open-label Study Comparing HyBryte (Synthetic Hypericin) To Valchlor (Mechlorethamine) Has Demonstrated Continued Improvement In HyBryte-treated Patients And Their Individual Lesions Even After Stopping Treatment

Evercore ISI Group analyst Mark Lipacis maintains Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Outperform and raises the price target from $98 to $122.

MRVL

Evercore ISI Group Maintains Outperform on Marvell Tech, Raises Price Target to $122

USPH

U.S. Physical Therapy Acquired A 75% Interest In Hand And Physical Therapy Practice With Eight Clinic Locations In Wyoming, With Approximately $6.5M In Annual Revenues And 43,000 In Annual Visits, Current Owners Retain A 25% Ownership Interest

CYTK

The FDA Has Accepted Cytokinetics' New Drug Application For Aficamten For Obstructive Hypertrophic Cardiomyopathy, PDUFA Target Action Date Set for September 26, 2025

<ul>
<li>In addition, XOMA Royalty will pay success-based consideration contingent on future development and commercial events to Pulmokine stockholders. &nbsp;XOMA Royalty's net royalties will range from the low to mid-single digits on commercial sales; additionally, the Company will retain up to $25 million of the milestone payments.&nbsp;</li>
</ul>

XOMA

XOMA Royalty Said It Owns An Economic Interest In Seralutinib, A Phase 3 Asset Being Studied In Pulmonary Arterial Hypertension, Through Its Acquisition Of Pulmokine For A $20M In Cash Payment

Deutsche Bank analyst Nate Svensson maintains Flywire (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYW#NASDAQ">FLYW</a>) with a Buy and raises the price target from $23 to $26.

FLYW

Deutsche Bank Maintains Buy on Flywire, Raises Price Target to $26

Northland Capital Markets analyst Tim Savageaux reiterates POET Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POET#NASDAQ">POET</a>) with a Outperform and raises the price target from $6 to $7.

Reiteration

POET

Northland Capital Markets Reiterates Outperform on POET Technologies, Raises Price Target to $7

UBS analyst Esther Rajavelu downgrades Applied Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>) from Buy to Neutral and lowers the price target from $13 to $2.

Downgrades

APLT

UBS Downgrades Applied Therapeutics to Neutral, Lowers Price Target to $2

Donald Trump&#8217;s election victory has prompted economists to revise their housing market forecasts. Many now predict mortgage rates will remain elevated through 2025 due to the <a href="https://www.benzinga.com/markets/24/11/42060564/trump-ties-housing-relief-to-mass-deportations-experts-say-not-so-fast">president-elect&#8217;s proposed trade and immigration policies</a>.
Don't Miss:
<ul>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
</ul>
After Trump&#8217;s win, Redfin shifted its 2025 mortgage rate projection from 6.1% to 6.8%. &#8220;The difference is Trump,&#8221; Daryl Fairweather, Redfin&#8217;s chief economist, told Bloomberg. &#8220;The market seems to be pricing in that he&#8217;ll move forward with at least some of the tariffs, but it&#8217;s really hard to know what Trump will do.&#8221;
The potential impact stems from several key policy proposals. Trump&#8217;s planned tariffs—up to 20% on all imports and 60% on Chinese goods—could drive inflation higher as companies pass increased costs to consumers. Additional tax cuts might expand the national deficit, putting upward pressure on long-term interest rates.
See Also: Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a>
Capital Economics economist Thomas Ryan expects mortgage rates to hover around 7% through the end of this year, dropping just 0.25% by the end of 2025. &#8220;There was a view that rates would gradually fall, but that no longer seems to be the case,&#8221; Ryan told Bloomberg. &#8220;The housing market is going to stay frozen — as it is — for longer than we and other economists had expected.&#8221;
While the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42170135/its-the-most-wonderful-time-of-the-year-for-the-stock-market-history-says">stock market rallied post-election</a>, bond markets have shown more caution. Barclays economists raised inflation projections for the next two years while lowering economic growth expectations, citing tariff proposals and potential immigration restrictions.
The construction industry faces particular challenges under Trump&#8217;s immigration policies. &#8220;We need labor,&#8221; Nadia Evangelou, senior economist at the National Association of Realtors, told Bloomberg. &#8220;Sometimes homebuilders are not able to deliver affordable homes or the price point that people can afford to buy. And the reason is because of the labor shortage.&#8221;
Trending: Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a>
Mark Zandi, chief economist at Moody&#8217;s Analytics, suggests high rates could persist even longer. &#8220;I don&#8217;t think I&#8217;d count on mortgage rates coming down anytime until next fall, later next year,&#8221; he said. &#8220;And even then, I&#8217;m not sure. It really depends on what his policies are, how aggressively he pursues them.&#8221;
The market has already shown strain, with Redfin reporting increased time-on-market for homes. Properties now sit for a median of 41 days, about a week longer than last year. Current 30-year mortgage rates reached 6.93% on Monday, marking four straight weeks of increases, according to data from Mortgage News Daily.
Read Next:
<ul>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100.</a></li>
<li>Unlock the hidden potential of commercial real estate —<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a></li>
</ul>

Mortgage Rates Near 7% Are Here To Stay? How Trump's Tariffs Could Hit Homebuyers Hard

B of A Securities analyst Ebrahim Poonawala maintains Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) with a Buy and raises the price target from $78 to $90.

B of A Securities Maintains Buy on Citigroup, Raises Price Target to $90

Baird analyst Shrenik Kothari maintains SentinelOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) with a Outperform and raises the price target from $30 to $32.

Baird Maintains Outperform on SentinelOne, Raises Price Target to $32

Baird analyst Brian Skorney reiterates Soleno Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>) with a Outperform and maintains $72 price target.

Comments

Point To Point Methodics

News

Latest news for Point To Point Methodics (OTC:PPMH) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga